Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Reduced serum cholesterol is linked to increased risks of depression and violent deaths.
• The connection between cholesterol levels and serotonin neurotransmission impairment requires further investigation.

Purpose of the Study:

• To investigate the effects of simvastatin therapy on serum/membrane cholesterol, erythrocyte membrane microviscosity, and platelet serotonin uptake in hypercholesterolemic patients.
• To explore the relationship between cholesterol reduction and serotonin transporter (SERT) activity during simvastatin treatment.

Main Methods:

• Pharmacotherapy with simvastatin was administered to 17 hypercholesterolemic patients.
• Measurements included serum and membrane cholesterol, erythrocyte membrane microviscosity, platelet serotonin uptake, and clinical parameters.
• Data were collected at baseline, 1 month, 2 months, and over 1 year of therapy.

Main Results:

• Simvastatin significantly decreased serum cholesterol and non-significantly decreased membrane cholesterol after 2 months.
• Platelet serotonin transporter (SERT) activity significantly increased after 1 month, with a tendency to decrease by 2 months.
• Membrane cholesterol and SERT activity returned to baseline levels after over 1 year of therapy; mood and behavioral parameters showed no significant changes.

Conclusions:

• Short-term simvastatin therapy (1-2 months) significantly increases SERT activity, suggesting a potential vulnerability period for depression, violence, or suicide.
• Long-term simvastatin therapy exhibits different effects on serotonin transmission compared to short-term treatment.
• The findings highlight the dynamic relationship between cholesterol-lowering drugs, serotonin transport, and potential neuropsychiatric risks.